{"entity":{"id":"nct07802626","kind":"trial","name":"Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing","aka":[],"tldr":"A phase 3 trial of Guardant Reveal in Breast cancer, run by SWOG Cancer Research Network, not yet recruiting.","summary":"Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing is a phase 3 interventional study registered as NCT07802626 by SWOG Cancer Research Network, with 1084 participants planned, started 2026-10-30 and due to reach its primary completion in 2034-10-30. Interventions recorded: NSAI + CDK4/6i, NSAI + CDK4/6i + Capivasertib, Fulvestrant + CDK4/6i + Capivasertib, NSAI + CDK4/6i, Guardant Reveal. Conditions recorded: HR Positive/HER-2 Negative Breast Cancer.\n\nLinked to the drug Guardant Reveal because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.","status":"planned","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT07802626","url":"https://clinicaltrials.gov/study/NCT07802626"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["guardant-reveal"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07802626","phase":"3","setting":"MONITOR (Molecular Assessment and Identification of ctDNA and Optimizing Treatment for HR-positive, Her2-negative Metastatic Breast Cancer)","sponsor":"SWOG Cancer Research Network","enrolled":1084,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07802626/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"guardant-reveal","kind":"drug","name":"Guardant Reveal","route":"/drugs/guardant-reveal/"}]}}